Tag: Conjunctival hyperemia

Clinical studies have shown that bimatoprost 0.01% is equivalent in efficacy to bimatoprost 0.03% for lowering intraocular pressure (IOP) over 12 months, but with fewer side effects. The lower-concentration formulation was developed to improve the drug's tolerability, a significant factor for patients on long-term therapy.

In clinical trials, over 50% of patients using ROCK inhibitor eye drops reported experiencing conjunctival hyperemia (eye redness), making it the most common adverse reaction. Understanding what are the side effects of ROCK inhibitors is crucial, as this class of medication is frequently used to treat glaucoma and ocular hypertension.

In clinical trials, over 50% of patients using Rhopressa experienced conjunctival hyperemia, or eye redness. For those considering or currently using this medication, understanding what are the problems with rhopressa is crucial to manage expectations and ensure optimal treatment.